The Valley Desk

NCT03394365 · Interventional trial

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

Overall registry status Recruiting

Phase 3

Conditions Allogeneic Hematopoietic Cell Transplant, Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Lymphoproliferative Disorders, Solid Organ Transplant Complications, Stem Cell Transplant Complications

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov